Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Cellular's schizophrenia drug meeting trial goals, Britain's new mpox variant detection, proposed UK smoking bans, challenges in weight-loss medication access, CVS Health's strategy adaptation, South ...

to our New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. Interactions with the FDA continue with the goal of addressing ...

BURLINGTON, Mass., Nov. 05, 2024(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported busin ...

Massachusetts voters are weighing five ballot measures, including giving union rights to drivers for ride-hailing companies like Uber and Lyft ...

The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may ...

Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.

Massachusetts voters have five ballot questions to answer on Election Day that will play a major role in shaping education, ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Begin your TipRanks Premium journey today. Bristol-Myers Squibb (BMY) Company Description: Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in ...